Skip to main content
. 2014 Apr 30;15(5):7500–7512. doi: 10.3390/ijms15057500

Table 2.

Approved drugs for oral HBV treatment.

Characteristics Lamivudine Tenofovir Adefovir Entecavir Telbivudine
year of approval 1999 2001 2002 2006 2007
resistance after five years ca. 70% not found yet ca. 30% ca. 1% ca. 22%
medical assessment well tolerated, main concern: resistance less nephrotoxic than adefovir nephrotoxic, less prone to resistance than lamivudine well tolerated, more potent than lamivudine and adefovir well tolerated, high potency, resistances appear after one year